Nuvation Bio reported Q4 2025 net product revenue of USD 15.7 million, reflecting U.S. sales of IBTROZI, and collaboration and license agreements revenue of USD 26.2 million. For FY 2025, net product revenue was USD 24.7 million and collaboration and license agreements revenue was USD 38.2 million. Q4 2025 net loss was USD 36.6 million (USD 0.11 per share) and FY 2025 net loss was USD 204.6 million (USD 0.60 per share). Cash, cash equivalents and marketable securities totaled USD 529.2 million as of December 31, 2025. For business updates, Nuvation Bio said 216 new patients started IBTROZI in Q4 2025, bringing total new patient starts to 432 since the U.S. launch in the second half of June 2025, with an adoption rate it said is approximately six times greater than prior recent ROS1 TKI launches based on IQVIA data. The company also entered an exclusive license and collaboration agreement with Eisai on January 11, 2026, to develop and commercialize taletrectinib in Europe and additional countries outside the U.S., China and Japan. In its pipeline, Nuvation Bio highlighted published Phase 2 results for safusidenib in grade 2 IDH1-mutant glioma showing a 44% ORR and 88% of patients progression-free at 24 months, and said the SIGMA study protocol was amended to a Phase 3 pivotal trial, with the first patient enrolled in October 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603021605PR_NEWS_USPR_____NY98291) on March 02, 2026, and is solely responsible for the information contained therein.
Comments